全球肝癌新药研发临床试验进展总结

肝癌电子杂志 ›› 2024, Vol. 11 ›› Issue (4): 1-5.

• 专题 • 下一篇

全球肝癌新药研发临床试验进展总结

孙嘉阳¹, 胡威², 唐玉^3,*

1.遵义医科大学,贵州遵义 563006;
2.遵义医科大学附属医院肿瘤科,遵义医科大学附属医院早期临床研究病房,贵州遵义 563000;
3.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院药物临床试验研究中心,北京 100021

收稿日期:2024-12-24 出版日期:2024-12-30 发布日期:2025-02-25
通讯作者: ^*唐玉,E-mail: tangyu@cicams.ac.cn

Progress summary clinical trials of new drugs for liver cancer

Sun Jiayang¹, Hu Wei², Tang Yu^3,*

1. Zunyi Medical University, Zunyi 563006,Guizhou, China;
2. Department of Oncology, Hospital of Zunyi Medical University, Early Clinical Research Ward, Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China;
3. National Cancer Center / National Clinical Research Center for Cancer / Drug Clinical Trial Research Center of Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China

Received:2024-12-24 Online:2024-12-30 Published:2025-02-25
Contact: ^*Tang Yu, E-mail: tangyu@cicams.ac.cn

摘要/Abstract

摘要： 目的: 总结2020—2024年6月全球肝癌药物注册临床试验开展情况及发展趋势。
方法: 基于英国Informa公司旗下的Pharma Intelligence开发的Trialtrove数据库,提取2020—2024年全球范围启动的肝癌药物临床试验及涉及试验药物的相关信息,分析肝癌临床研究的年度增长情况、试验、药物特征及其相关因素。
结果: 研究统计时间段内,全球共开展了356个肝癌药物注册临床试验,占全部肿瘤治疗药物临床试验的4.3%,其中由国内企业发起 189 个（53.1%）。肝癌临床试验启动数量在2022年达到顶峰（101个）。在试验分期方面,Ⅰ期临床试验（含Ⅰ、Ⅱ期）是最常见的临床试验分期类型（266个,74.7%）;在试验适应证方面,针对晚期肝癌的药物研发所占的比例最高（324个,91.0%）。在所有试验药物中,所涉及的药物类型主要包括抗体类药物（48.0%）、小分子靶向药物（25.4%）、细胞基因类药物（15.4%）和抗体耦联药物（5.0%）。32个临床试验针对初治的不可手术或局部治疗的晚期肝癌的临床试验中,探索的主要试验性治疗方式是以免疫检查点抑制剂治疗为基础的药物联合治疗;针对晚期≥2线治疗患者开展的药物临床试验共262个,其中32个（12.2%）在免疫治疗失败的晚期肝癌患者中开展,目前均处于Ⅰ、Ⅱ期试验阶段,涉及的试验药物类型较为多样。
结论: 全球肝癌药物临床开发较为活跃,国内企业研发药物在其中发挥重要作用。在肝癌中,免疫治疗是最为活跃的药物研发领域;在后线肝癌临床试验中,细胞基因治疗也是重要的临床研究领域。建议国内企业加大针对肝癌新药研发投入,挖掘更多新靶点和新机制作用药物,拓宽肝癌治疗的可能方向。

关键词: 肝癌, 药物, 临床试验, 免疫治疗, 细胞基因治疗

Abstract: Objective: To summarize the development trend of global clinical trials of primary hepatic cancer(HCC) from 2020 to June 2024.
Methods: Based on the Trialtrove database developed by Informa Pharma Intelligence (London, UK), the clinical trials of liver cancer and the related medicines launched from 2020 to 2024 were extracted. The annual growth rate, the characteristics of trials and tested products were analyzed.
Results: During the statistical period, a total of 356 clinical trials for HCC were carried out worldwide, accounting for 4.3% of all anti-cancer clinical trials. Among them, 189 (53.1%) were initiated by domestic companies. The number of clinical trials for HCC peaked in 2022 (101 trials). Phase I(including phase Ⅰ/Ⅱ) clinical trials were the most common trial phase type (266 trials, 74.7%). In terms of trial indications, drug development for advanced HCC accounted for the highest proportion (324 trials, 91.0%). Among all the investigational drugs, the types of drugs involved mainly included antibody drugs (48.0%), small molecule targeted drugs (25.4%), cell and gene therapy (15.4%) and antibody-drug conjugate (5.0%). Thirty-two clinical trials focused on first line treatment for late-stage HCC. Among them, the main investigational treatment modality was combined immunotherapy based on immune checkpoint inhibitors. A total of 262 clinical trials were conducted for patients with advanced HCC progressed after previous treatment, of which 32 trials (12.2%) were carried out in patients failed immunotherapy. All the 32 trials were in phase Ⅰ/Ⅱ trials, involving a variety of experimental drug types.
Conclusions: The clinical development of liver cancer drugs is active in the world, and domestic enterprises play an important role. In liver cancer, immunotherapy is the most active field of drug development. While in the clinical trials including heavily treated HCC patients, cell and gene therapy is also an important clinical research area. It is suggested that domestic enterprises should increase investment in the development of novel drugs for liver cancer, explore more new targets and drugs with new mechanisms, and broaden the possible directions of liver cancer treatment.

Key words: Liver cancer, Drugs, Clinical trial, Immunotherapy, Cellular gene therapy

孙嘉阳, 胡威, 唐玉. 全球肝癌新药研发临床试验进展总结[J]. 肝癌电子杂志, 2024, 11(4): 1-5.

Sun Jiayang, Hu Wei, Tang Yu. Progress summary clinical trials of new drugs for liver cancer[J]. Electronic Journal of Liver Tumor, 2024, 11(4): 1-5.

参考文献

[1] BRAY F, LAVERSANNE M, SUNG H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] GLOBAL BURDEN OF DISEASE LIVER CANCER COLLABORATION, AKINYEMIJU T, ABERA S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.
[3] 孙俪洋,潘扬勋,陈敏山.2023年度肝癌治疗研究现状与问题[/CDJ].肿瘤综合治疗电子杂志,2024,10(1):19-24.
[4] RS FINN, S QIN, M IKEDA, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Eng J Med, 2020, 382(20): 1894-1905.
[5] 中国临床肿瘤学会指南工作委员会.《中国临床肿瘤学会原发性肝癌诊疗指南》(2024版)[M].北京:人民卫生出版社, 2024:46-48.
[6] JIN Z C, ZHONG B Y, CHEN J J, et al.Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study[J]. Eur Radiol, 2023, 33(12): 8669-8681.
[7] 陈湘麒,张楠,赵海涛.肝细胞癌免疫联合靶向治疗方案中的瓶颈与对策[J].中国实用外科杂志,2024,44(9):1021-1027.
[8] SCHOENFELD A J, HELLMANN M D.Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020, 37(4): 443-455.
[9] Informa Pharma Intelligence. Informa intelligence[DB/OL](2022-10-28)[2024-12-10]. https://www.informa.com/divisions/informaintelligence.
[10] MCGLYNN K A, PETRICK J L, GROOPMAN J D, et al.Liver cancer: progress and priorities[J]. Cancer Epidemiol Biomarkers Prev, 2024, 33(10): 1261-1272.
[11] REN Z, XU J, BAI Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7):977-990.
[12] IQVIA INSTITUTE.Global oncology trends 2024: outlook to 2028[Z]. https://www.iqvia.com/../global-oncology-trends-2024.
[13] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[14] IQVIA INSTITUTE. Global trends in R&D2023: activity, productivity, and enablers[Z].https://www.farmindustria.it/app/uploads/2023/02/iqvia-institute-global-trends-in-rd-2023-forweb.pdf.
[15] ZHOU F, SHANG W, YU X, et al.Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment[J]. Med Res Rev, 2018, 38(2): 741-767.
[16] LU J, JIANG G.The journey of CAR-T therapy in hematological malignancies[J]. Mol Cancer, 2022, 21(1): 194.
[17] MA R, LI Z, CHIOCCA E A, et al.The emerging field of oncolytic virus-based cancer immunotherapy[J]. Trends Cancer, 2023, 9(2): 122-139.
[18] LIU N, XIAO X, ZHANG Z, et al.Advances in cancer vaccine research[J]. ACS Biomater Sci Eng, 2023, 9(11): 5999-6023.
[19] MELERO I, YAU T, KANG Y K, et al.Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040[J]. Ann Oncol, 2024, 35(6): 537-548.
[20] ABOU-ALFA G, LAU G, KUDO M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J]. NEJM Evid, 2022, 1(8): EVIDoa2100070.

全球肝癌新药研发临床试验进展总结

Progress summary clinical trials of new drugs for liver cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	向桂林, 宋书珲, 段石杰, 房虹, 唐玉, 刘福囝. 溶瘤病毒在晚期肝癌治疗中的研究进展[J]. 肝癌电子杂志, 2024, 11(4): 13-18.
[2]	宁艳婷, 夏娟, 吴舒, 张琦, 李晓青, 车旭, 占正寅. 肝癌靶向治疗中手足皮肤反应研究进展[J]. 肝癌电子杂志, 2024, 11(4): 54-59.
[3]	梁骏, 杨振云, 张耀军, 陈敏山, 胡丹旦. 混合型肝癌免疫治疗疗效及安全性的初步观察[J]. 肝癌电子杂志, 2024, 11(3): 20-24.
[4]	朱润泽, 穆少伟, 李照, 朱继业, 高杰. 手术切除后混合型肝癌、肝细胞癌及肝内胆管细胞癌的临床特征及预后分析：倾向性匹配分析[J]. 肝癌电子杂志, 2024, 11(3): 25-32.
[5]	赵航祺, 马小雯, 张天爱, 李柏峰. 基于生物信息学分析跨膜蛋白132A在肝癌中的表达及其临床意义[J]. 肝癌电子杂志, 2024, 11(3): 33-41.
[6]	邵堂, 郑方澍, 吴军. 2012—2021年中国居民肝癌死亡率发展趋势研究[J]. 肝癌电子杂志, 2024, 11(3): 54-57.
[7]	吴文琪, 王皓, 王玉霞. 肝癌相关多原发肿瘤的临床特征分析[J]. 肝癌电子杂志, 2024, 11(2): 33-36.
[8]	刘曼琪, 徐梦圆, 单天昊, 赵宏, 曾红梅, 蔡建强. 2022年全球肝癌与胆囊癌发病死亡及2050年预测分析[J]. 肝癌电子杂志, 2024, 11(2): 53-60.
[9]	张永琪, 李照. 不可切除肝内胆管癌的治疗方法研究进展[J]. 肝癌电子杂志, 2024, 11(2): 89-93.
[10]	董杰杰, 张彤, 李小争, 姚鹏. 潜在可切除中国肝癌分期Ⅲa期肝癌转化后根治性切除1例[J]. 肝癌电子杂志, 2024, 11(2): 100-103.
[11]	孟庆华. 《肝癌转化治疗中肝功能全程管理中国专家共识（2022版）》解读[J]. 肝癌电子杂志, 2024, 11(2): 104-108.
[12]	李梅, 乔蓓, 张志豪. 经导管动脉化疗栓塞术联合射频消融术治疗大肝癌的疗效及安全性的Meta分析[J]. 肝癌电子杂志, 2024, 11(1): 9-15.
[13]	梁人山, 张育, 陈祖涛, 冯婷婷. 液体活检在肝癌中的研究进展[J]. 肝癌电子杂志, 2024, 11(1): 30-33.
[14]	都孟雅, 陈佩娟, 孙景苑. 针对性护理管理对放射治疗后肝癌患者的干预效果分析[J]. 肝癌电子杂志, 2024, 11(1): 34-37.
[15]	孙亚莉, 同欢庆, 袁泼棉, 刘乐, 吴娜, 周侃, 翟九玲. 接纳与承诺疗法心理干预对原发性肝癌患者负性情绪和治疗依从性的影响[J]. 肝癌电子杂志, 2024, 11(1): 38-41.